Lactoferricin B vs LL-37 — Peptide Comparison

Lactoferricin B vs LL-37 — Peptide Comparison Lactoferricin B vs LL-37 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Lactoferricin B 1–10 mg LL-37 0.5–1.6 mg/mL (topical) Frequency Multiple times daily Once daily Administration Oral (research — resistant to gastric digestion) Topical application (wound healing) Cycle Length 4-6 weeks 12+ weeks Onset Speed Rapid (hours to days) Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase 1-2) Efficacy Fighting Germs Cancer Cell Targeting Immune Support Wound Healing Fighting Infections Immune Boost Technical Data Molecular Formula Approximately C142H224N46O34S2 (varies slightly by reported sequence) Molecular Weight ~3,126 Da (25-amino-acid bovine lactoferricin B) Half-Life Plasma half-life: minutes (proteolytic degradation); gastrointestinal persistence: hours (relative resistance to trypsin and chymotrypsin compared to unstructured peptides); beta-sheet structure and disulfide bond provide moderate protease resistance Bioavailability Generated endogenously during gastric digestion of dietary lactoferrin; partially resistant to further proteolytic degradation due to beta-sheet structure and disulfide bond; systemic bioavailability limited by intestinal proteases and hepatic metabolism CAS Number 146897-68-9 C205H340N60O53 4,493.26 Da Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery 154947-66-7 Protocols starting 0.5 mg/mL gel Twice weekly 4 weeks Lowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4]. standard 1.6 mg/mL gel Mid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4]. Applications Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms Lactoferricin B is particularly well-suited for individuals focused on research into dairy-derived antimicrobial peptides and natural innate defense mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Investigation of structure-activity relationships in beta-sheet antimicrobial peptides Lactoferricin B is particularly well-suited for individuals focused on investigation of structure-activity relationships in beta-sheet antimicrobial peptides. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry Lactoferricin B is particularly well-suited for individuals focused on preclinical development of anticancer peptides targeting membrane phospholipid asymmetry. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion Lactoferricin B is particularly well-suited for individuals focused on understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Anti-biofilm strategies for chronic wound infections and medical device-associated infections LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Boosting innate immune defense in immunocompromised or aging individuals LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety P Common Mild GI discomfort Bitter taste Local irritation (topical use) Mild flatulence Uncommon Allergic reaction in milk-sensitive individuals Serious Hemolytic activity at high concentrations Local site irritation Transient stinging or burning Mild perilesional erythema Increased wound exudate Allergic contact reaction Hemolytic activity at systemic concentrations Research Status FDA Status Research compound Safety Overview Lactoferricin B is a 25-amino acid peptide fragment of human lactoferrin with a well-documented natural history—derived from a dietary protein that humans consume in breast milk and dairy products. Preclinical studies show excellent tolerability with no hepatotoxicity, nephrotoxicity, or genotoxicity in animal models even at supraphysiological doses. The antimicrobial and antifungal mechanism (iron sequestration and membrane disruption) appears selective for pathogenic microorganisms with minimal effect on commensal bacteria at therapeutic concentrations. Contraindications xKnown allergy to bovine milk proteins or lactoferrin — cross-reactivity possible xPregnancy and breastfeeding — insufficient safety data for therapeutic-dose lactoferricin supplementation xActive hemolytic conditions — at higher concentrations lactoferricin shows some hemolytic activity that may worsen hemolysis xIron overload conditions (hemochromatosis) — lactoferricin retains some iron-binding capacity from the parent lactoferrin molecule LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications. xKnown hypersensitivity to cathelicidin peptides or formulation components xActive hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity xPregnancy and breastfeeding — insufficient reproductive safety data from clinical trials xSevere renal impairment — peptide clearance may be altered Decision Guide Choose Lactoferricin B if... Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms Investigation of structure-activity relationships in beta-sheet antimicrobial peptides Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion Choose LL-37 if... Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) Anti-biofilm strategies for chronic wound infections and medical device-associated infections Boosting innate immune defense in immunocompromised or aging individuals